NCT02345824View on ClinicalTrials.gov

Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma

PHASE1UnknownINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

January 31, 2020

Conditions

GlioblastomaGlioma

Interventions

DRUG

Ribociclib

CDK4/6 INHIBITOR

Trial Locations (1)

22908

University of Virginia Health System, Charlottesville

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Virginia

OTHER